Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-521 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-521 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-247 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
filingDate |
2019-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e3989e9a68ddda273ef74f81646764e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4af22ff2f0d9c6fad1414a44acc9413f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b1f773a58577d31abc2d1fc87634b28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69965256c6b3810fa69244ae83d2c564 |
publicationDate |
2020-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2020060580-A |
titleOfInvention |
Anti-IL4-IL13 bispecific antibody |
abstract |
PROBLEM TO BE SOLVED: To determine whether a dose containing a double V region antibody-like protein or a fragment thereof administered to a human subject specifically binds to IL-4 or IL-13 in the human subject. SOLUTION: (a) administering the dose to the human subject; (b) measuring the amount of TARC / CCL17 protein in a blood, plasma, or serum sample drawn from the human subject. , A decrease in the amount of TARC / CCL17 in the blood sample as compared to the amount of TARC / CCL17 in the subject measured before the dose is administered, the dual V to IL-4 or IL-13. A method comprising signaling binding of a region antibody-like protein or fragment thereof; and (c) increasing or decreasing the dose depending on the decrease in TARC / CCL17 measured in step (b). [Selection diagram] None |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-112021002033-T5 |
priorityDate |
2014-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |